Low Tumor Growth Rates During Active Surveillance of Thyroid CA

Share this content:
Low Tumor Growth Rates During Active Surveillance of Thyroid CA
Low Tumor Growth Rates During Active Surveillance of Thyroid CA

FRIDAY, Sept. 1, 2017 (HealthDay News) -- Among patients with low-risk papillary thyroid cancer (PTC), the rates of tumor growth during active surveillance are low, according to a study published online Aug. 31 in JAMA Otolaryngology-Head & Neck Surgery.

R. Michael Tuttle, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues describe the kinetics of PTC tumor growth during active surveillance in a cohort of 291 patients undergoing active surveillance for low-risk PTC.

The researchers found that growth in tumor diameter of 3 mm or more occurred in 3.8 percent of patients, with a cumulative incidence of 2.5 and 12.1 percent at two and five years, respectively. During active surveillance, no regional or distant metastases developed. Three-dimensional measurements of tumor volume allowed for earlier identification of growth in all cases (median, 8.2 months before increase in tumor diameter). Younger age at diagnosis (hazard ratio per year, 0.92) and risk category at presentation (hazard ratio for inappropriate, 55.17) correlated independently with the likelihood of tumor growth. Kinetics demonstrated a classic exponential growth pattern among tumors experiencing volume growth, with a median doubling time of 2.2 years.

"Serial measurement of tumor volumes may facilitate early identification of tumors that will continue to grow and thereby inform the timing of surveillance imaging and therapeutic interventions," the authors write.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »